Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs
Costs for conversion of Ordinary Shares into ADS s waived by JP Morgan Chase for initial four weeks after today
LEIDEN, Netherlands, Dec. 22, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, today separately announced that in connection with the listing of American Depositary Shares ( ADSs ) representing ordinary shares of nominal value of €0.01 each in the capital of the Company ( Ordinary Shares ) on the Nasdaq Global Market ( Nasdaq ), the United States Securities and Exchange Commission has declared effective registration statements on Form F-1 and F-6 with respect to such securities, Nasdaq has approved the ADSs for listing, and ADSs will begin tra
American Aires Inc.: American Aires Receives Additional $546,000 from Warrants Exercised
Company or
Aires ) is pleased to announce that, further to the Company s news release of October 7, 2020, the Company has received additional proceeds of $546,000 from the exercise of an additional 3,900,000 warrants. The exercise of these warrants resulted in 3,900,000 common shares being issued, increasing the number of common shares outstanding in the share capital of the Company to 118,620,000. An additional 17.1 million warrants that are in-the-money remain outstanding, which, if exercised, would result in the Company receiving an additional $2.39 million. The proceeds will be used for general working capital purposes.
About American Aires Inc. American Aires Inc. is a nanotechnology company which has developed proprietary silicon-based microprocessors that reduce the harmful effects of electromagnetic radiation (EMR). The technology was developed by a team of highly credited scientist
Alaska Communications Announces Amendment of Amended & Restated Merger Agreement with Macquarie Capital and GCM Grosvenor to Increase Consideration to $3 26 per Share businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.
Price Analysis
The current crypto bull run has been spearheaded by Bitcoin (BTC). As the United States Securities and Exchange Commission has previously hinted that Bitcoin is not a security, the regulator’s current lawsuit against Ripple is unlikely to stop the institutional inflow of money into Bitcoin.
However, a few altcoins that may be at risk of facing a similar fate as Ripple could face selling pressure. Due to a change in sentiment, retail investors may sell some of their altcoin holdings and shift to Bitcoin.
Even retail investors who plan to spend their stimulus checks for buying crypto-assets may prefer Bitcoin over altcoins. So, while XRP faces selling pressure, the lawsuit may prove to be bullish for Bitcoin.
The United States Securities and Exchange Commission (SEC) announced that Chinese coffee giant Luckin Coffee has agreed to pay a $180 million penalty following charges that the company defrauded investors.
The settlement offer comes eight months after the SEC announced that Luckin had confirmed its former COO and other top company officials had conspired to fabricate more than $300 million in sales in order to appease investors.
Following a months-long investigation, the SEC formalized its charges against the three-year-old company last week, alleging that the company misstated its revenue, expenses and net operating losses in “an effort to falsely appear to achieve rapid growth and increased profitability and to meet the company’s earnings estimates.”